{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T23:52:53Z","timestamp":1790553173658,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.jconrel.2016.10.001","type":"journal-article","created":{"date-parts":[[2016,10,8]],"date-time":"2016-10-08T20:05:28Z","timestamp":1475957128000},"page":"78-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Effect of intraocular pressure (IOP) and choroidal circulation on controlled episcleral drug delivery to retina\/vitreous"],"prefix":"10.1016","volume":"243","author":[{"given":"Jie","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bifei","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2016.10.001_bb0005","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0161-6420(92)31871-8","article-title":"Prevalence of age-related maculopathy. The beaver dam eye study","volume":"99","author":"Klein","year":"1992","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jconrel.2016.10.001_bb0010","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.jconrel.2016.10.001_bb0015","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1001\/jamaophthalmol.2015.1823","article-title":"Incidence, risk factors, and timing of elevated intraocular pressure after intravitreal triamcinolone acetonide injection for macular edema secondary to retinal vein occlusion: SCORE study report 15","volume":"133","author":"Aref","year":"2015","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.jconrel.2016.10.001_bb0020","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1089\/jop.2014.0094","article-title":"Intravitreal triamcinolone acetonide in the treatment of ophthalmic inflammatory diseases with macular edema: a meta-analysis study","volume":"31","author":"Bucolo","year":"2015","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2016.10.001_bb0025","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1167\/tvst.4.2.4","article-title":"One-year outcomes of the SAVE study: sirolimus as a therapeutic approach for UVEitis","volume":"4","author":"Ibrahim","year":"2015","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.jconrel.2016.10.001_bb0030","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1167\/iovs.14-15877","article-title":"Intravitreal sirolimus for the treatment of geographic atrophy: results of a phase I\/II clinical trial","volume":"56","author":"Petrou","year":"2015","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2016.10.001_bb0035","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12348-015-0044-1","volume":"5","author":"Vigil","year":"2015","journal-title":"J. Ophthalmic. Inflamm. Infect."},{"key":"10.1016\/j.jconrel.2016.10.001_bb0040","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/j.ophtha.2014.07.002","article-title":"A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study","volume":"121","author":"Gillies","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jconrel.2016.10.001_bb0045","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ophtha.2013.06.033","article-title":"Dexamethasone implant anterior chamber migration: risk factors, complications, and management strategies","volume":"121","author":"Khurana","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jconrel.2016.10.001_bb0050","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/eye.2014.13","article-title":"A review of anti-VEGF agents for proliferative diabetic retinopathy","volume":"28","author":"Osaadon","year":"2014","journal-title":"Eye"},{"key":"10.1016\/j.jconrel.2016.10.001_bb0055","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"G. Comparison of Age-related Macular Degeneration Treatments Trials Research","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jconrel.2016.10.001_bb0060","doi-asserted-by":"crossref","first-page":"310","DOI":"10.4239\/wjd.v4.i6.310","article-title":"Ranibizumab in diabetic macular edema","volume":"4","author":"Krispel","year":"2013","journal-title":"World J. Diabetes"},{"key":"10.1016\/j.jconrel.2016.10.001_bb0065","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ajo.2011.01.053","article-title":"Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration","volume":"152","author":"Day","year":"2011","journal-title":"Am J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2016.10.001_bb0070","first-page":"2363","article-title":"VEGF inhibition study in ocular neovascularization-1 (VISION-1): safety evaluation from the pivotal MacugenTM (pegaptanib sodium) clinical trials","volume":"45","author":"D'Amico","year":"2004","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2016.10.001_bb0075","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jconrel.2010.08.028","article-title":"Barrier analysis of periocular drug delivery to the posterior segment","volume":"148","author":"Ranta","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2016.10.001_bb0080","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1463-5224.2010.00835.x","article-title":"Advancements in ocular drug delivery","volume":"13","author":"Weiner","year":"2010","journal-title":"Vet. Ophthalmol."},{"key":"10.1016\/j.jconrel.2016.10.001_bb0085","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.actbio.2013.09.022","article-title":"Sustained release of triamcinolone acetonide from an episcleral plaque of multilayered poly-epsilon-caprolactone matrix","volume":"10","author":"Meng","year":"2014","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2016.10.001_bb0090","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1167\/iovs.04-1414","article-title":"The influence of intraocular pressure on the transscleral diffusion of high-molecular-weight compounds","volume":"46","author":"Cruysberg","year":"2005","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2016.10.001_bb0095","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.exer.2005.08.007","article-title":"A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide","volume":"82","author":"Robinson","year":"2006","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.jconrel.2016.10.001_bb0100","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0014-4835(03)00211-2","article-title":"Drug delivery through the sclera: effects of thickness, hydration, and sustained release systems","volume":"78","author":"Lee","year":"2004","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.jconrel.2016.10.001_bb0105","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1089\/108076802321021108","article-title":"In vitro human scleral permeability of fluorescein, dexamethasone-fluorescein, methotrexate-fluorescein and rhodamine 6G and the use of a coated coil as a new drug delivery system","volume":"18","author":"Cruysberg","year":"2002","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2016.10.001_bb0110","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1089\/jop.2012.0226","article-title":"The effect of ocular pigmentation on transscleral delivery of triamcinolone acetonide","volume":"29","author":"Du","year":"2013","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2016.10.001_bb0115","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0169-409X(01)00193-4","article-title":"Transscleral drug delivery for posterior segment disease","volume":"52","author":"Geroski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2016.10.001_bb0120","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.exer.2010.01.001","article-title":"Episcleral clearance of sodium fluorescein from a bioerodible sub-tenon's implant in the rat","volume":"90","author":"Chan","year":"2010","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.jconrel.2016.10.001_bb0125","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.ophtha.2007.02.010","article-title":"Randomized trial of peribulbar triamcinolone acetonide with and without focal photocoagulation for mild diabetic macular edema \u2013 a pilot study","volume":"114","author":"Chew","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jconrel.2016.10.001_bb0130","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.ajo.2011.03.033","article-title":"Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema","volume":"152","author":"Sohn","year":"2011","journal-title":"Am J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2016.10.001_bb0135","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1097\/IAE.0b013e31824fd384","article-title":"Comparison of intraocular pressure elevation after anterior versus posterior subtenon triamcinolone acetonide acetate injection: a retrospective study","volume":"32","author":"Liu","year":"2012","journal-title":"Retina"},{"key":"10.1016\/j.jconrel.2016.10.001_bb0140","article-title":"Perioperative pharmacological management of rhoroidal retachment associated with rhegmatogenous retinal retachment","author":"Shen","year":"2015","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.jconrel.2016.10.001_bb0145","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/00061198-200102000-00005","article-title":"Diurnal variation of episcleral venous pressure in healthy patients: a pilot study","volume":"10","author":"Blondeau","year":"2001","journal-title":"J. Glaucoma"},{"key":"10.1016\/j.jconrel.2016.10.001_bb0150","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1007\/s11095-008-9691-3","article-title":"Computer modeling of drug delivery to the posterior eye: effect of active transport and loss to choroidal blood flow","volume":"25","author":"Balachandran","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2016.10.001_bb0155","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/IAE.0b013e31821e1f7c","article-title":"Further characterization of ocular safety profile of commercially available preserved and preservative-free triamcinolone acetonide","volume":"32","author":"Li","year":"2012","journal-title":"Retina"},{"key":"10.1016\/j.jconrel.2016.10.001_bb0160","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1167\/iovs.12-11460","article-title":"Different intravitreal properties of three triamcinolone formulations and their possible impact on retina practice","volume":"54","author":"Chen","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2016.10.001_bb0165","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1463-5224.2011.00881.x","article-title":"Effect of acute intraocular pressure elevation on blood flow velocity and resistance in the rabbit ophthalmic artery","volume":"14","author":"Yang","year":"2011","journal-title":"Vet. Ophthalmol."},{"key":"10.1016\/j.jconrel.2016.10.001_bb0170","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/bjo.2009.172106","article-title":"Characterisation of systemic and ocular drug level of triamcinolone acetonide following a single sub-tenon injection","volume":"94","author":"Nan","year":"2010","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2016.10.001_bb0175","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ophtha.2014.09.027","article-title":"Transscleral permeation of subtenon triamcinolone in different vitreoretinal diseases","volume":"122","author":"Shen","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jconrel.2016.10.001_bb0180","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/(SICI)1097-4628(19970314)63:11<1499::AID-APP12>3.0.CO;2-Y","article-title":"Comparison of the effect of ethylene oxide and gamma-irradiation on selected tyrosine-derived polycarbonates and poly(l-lactic acid)","volume":"63","author":"Hooper","year":"1997","journal-title":"J. Appl. Polym. Sci."},{"key":"10.1016\/j.jconrel.2016.10.001_bb0185","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1016\/j.polymdegradstab.2010.06.007","article-title":"Biodegradable polymer matrix nanocomposites for tissue engineering: a review","volume":"95","author":"Armentano","year":"2010","journal-title":"Polym. Degrad. Stab."},{"key":"10.1016\/j.jconrel.2016.10.001_bb0190","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1163\/15685620260449723","article-title":"Effect of gamma, ethylene oxide, electron beam, and plasma sterilization on the behaviour of SR-PLLA fibres in vitro","volume":"13","author":"Nuutinen","year":"2002","journal-title":"J. Biomater. Sci. Polym. Ed."},{"key":"10.1016\/j.jconrel.2016.10.001_bb0195","first-page":"150","article-title":"Effect of circulation on the disposition and ocular tissue distribution of 20nm nanoparticles after periocular administration","volume":"14","author":"Amrite","year":"2008","journal-title":"Mol. Vis."},{"key":"10.1016\/j.jconrel.2016.10.001_bb0200","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1007\/s11095-004-7669-3","article-title":"Assessment of subconjunctival delivery with model ionic permeants and magnetic resonance imaging","volume":"21","author":"Li","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2016.10.001_bb0205","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1167\/iovs.04-0091","article-title":"Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging","volume":"45","author":"Kim","year":"2004","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2016.10.001_bb0210","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1167\/iovs.08-1989","article-title":"Pharmacokinetics of intraocular drug delivery of Oregon Green 488-labeled triamcinolone by subtenon injection using ocular fluorophotometry in rabbit eyes","volume":"49","author":"Lee","year":"2008","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2016.10.001_bb0215","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0002-9394(14)70131-X","article-title":"Peribulbar corticosteroid injection: vitreal and serum concentrations after dexamethasone disodium phosphate injection","volume":"123","author":"Weijtens","year":"1997","journal-title":"Am J. Ophthalmol."},{"key":"10.1016\/j.jconrel.2016.10.001_bb0220","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1080\/09273940802687838","article-title":"Vitreous concentration of triamcinolone acetonide after a single transseptal depot injection","volume":"17","author":"Silva","year":"2009","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.jconrel.2016.10.001_bb0225","first-page":"3054","article-title":"The effect of intraocular pressure on human and rabbit scleral permeability","volume":"40","author":"Rudnick","year":"1999","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jconrel.2016.10.001_bb0230","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.actbio.2016.04.014","article-title":"Episcleral drug film for better-targeted ocular drug delivery and controlled release using multilayered poly-\u03b5-caprolactone (PCL)","volume":"37","author":"Sun","year":"2016","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2016.10.001_bb0235","first-page":"1893","article-title":"Human scleral permeability. Effects of age, cryotherapy, transscleral diode laser, and surgical thinning","volume":"36","author":"Olsen","year":"1995","journal-title":"Invest. Ophthalmol. Vis. Sci."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365916308938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365916308938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T16:51:51Z","timestamp":1536339111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365916308938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":47,"alternative-id":["S0168365916308938"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2016.10.001","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of intraocular pressure (IOP) and choroidal circulation on controlled episcleral drug delivery to retina\/vitreous","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2016.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}